Stroke Central Atlantic Network for Research (SCANR)

根据最初的提议：SCANR，中风中大西洋研究网络的总部设在中部- 大西洋区，总部设在华盛顿特区和弗吉尼亚州夏洛茨维尔。SCANR位于 中风带，华盛顿和巴尔的摩的中风发病率都很高。SCANR包括四个卡内基研究1 大学(乔治敦大学和乔治华盛顿大学；弗吉尼亚大学和马里兰大学)，两个CTSA，一个 翻译研究所(Thriv)，美国新闻与世界报道国家荣誉榜医院(国家儿童医院) 医疗中心)，华盛顿特区最大的医院(MedStar华盛顿医院中心)，两所历史上的黑人大学 (霍华德大学和华盛顿特区大学)和NINDS壁内卒中计划。 SCANR网站在2016年评估了4100多例急性中风，其中50%是黑人/非裔美国人。我们由NINDS资助的试验 招募工作非常出色，筛选所有符合条件的患者并登记参加StrokeNet试验：Defuse 3，Mistie 3，HiDef， 狂想曲、SIRE、POINT和MR WITENCE，以及NINDS资助的额外试验。SCANR还包括 SIRE国家协调中心(UVA，约翰斯顿-PI)，以及CREST-2注册和成像核心(UMB，LAL)。 SCANR 2.0继续拥有使SCANR 1.0成为StrokeNet有力竞争者的所有优秀特性 精选：儿童卒中和卒中康复、患者群体和创新的健康招募做法 差异研究，以及与NINDS壁内卒中计划的链接。这些优势将脱颖而出， StrokeNet管道中的儿科、康复和儿科康复试验。SCANR 2.0包括UVA作为高性能站点 用于急性治疗和预防试验。UVA还提供生物标记物、遗传学和院前研究方面的专业知识。 UVA和UMB的加入使SCANR成为一个真正的区域协调中心。 SCANR 2.0的研究专长包括多模式成像、微生物学、多组学、神经康复试验、大脑 刺激和机器人技术。我们处于有利地位，可以将早期的NINDS内部研究转化为外部研究 布景。我们有招募大量特定脑血管表型(颈动脉)的记录 夹层、脑静脉血栓形成、脑淀粉样血管病等)。我们的学术康复医院联盟是 太棒了。我们目前有四个试验提案提交给StrokeNet，处于该过程的不同阶段。我们现有的 参与者招募和保留核心(PRRO Core)在StrokeNet网络中发挥了领导作用。 SCANR调查人员在国家StrokeNet指导委员会和核心部门任职。我们的StrokeNet伙伴有不同的 临床背景(2名血管神经科医生，1名PT博士，1名OT)，随后，他们成功地竞争了外部 供资(TL-2、KL-2、AHA)。他们有机会在我们的中部地区进行出色的研究、培训和指导- 大西洋研究机构，为他们从事富有成效的研究事业做准备。SCANR调查人员最近成功 制定了新的国家康复研究K12计划。我们目前有5个相关的奖学金项目 以及在SCANR 2.0站点的三个成人神经科住院医师。这项培训结合了强大的多学科临床和 在中风方面的研究专长，具有丰富的临床科学家的研究和职业发展经验。

FROM ORIGINAL PROPOSAL: SCANR, the Stroke Central Atlantic Network for Research is based in the Mid- Atlantic region and headquartered in Washington, DC, and Charlottesville, VA. SCANR is located on the edge of the Stroke Belt, and both DC and Baltimore have high stroke incidence. SCANR includes four Carnegie Research 1 universities (Georgetown and George Washington Universities; the Universities of Virginia and Maryland), two CTSAs, a translational research institute (THRIV), a US News & World Report National Honor Roll Hospital (Children's National Medical Center), the largest hospital in DC (MedStar Washington Hospital Center), two Historically Black Universities (Howard University and University of DC) and the NINDS Intramural Stroke Program. SCANR sites evaluated over 4100 acute strokes in 2016, >50% were Black/African American. Our NINDS-funded trial recruitment is excellent, screening all eligible patients for and enrolling in StrokeNet trials: DEFUSE 3, MISTIE 3, HiDef, Rhapsody, SHINE, POINT, and MR WITNESS, along with additional NINDS-funded trials. SCANR also includes the National Coordinating Center for SHINE (UVa, Johnston-PI), and the CREST-2 registry and imaging core (UMB, Lal). SCANR 2.0 continues to have all of the excellent qualities that made SCANR 1.0 a strong contender for StrokeNet selection: pediatric stroke and stroke rehabilitation, patient populations and innovative recruitment practices for health disparities research, and the link to the NINDS Intramural Stroke Program. These strengths will stand out with the pediatric, rehab, and pediatric rehab trials in the StrokeNet pipeline. SCANR 2.0 includes UVa as a high-performing site for acute treatment and prevention trials. UVa also provides expertise in biomarkers, genetics, and prehospital research. The addition of UVa and UMB made SCANR a truly regional Coordinating Center. SCANR 2.0 research expertise includes multimodal imaging, microbiomics, multi-omics, Neurorehabilitation trials, brain stimulation, and robotics. We are well positioned to translate early phase NINDS intramural studies into the extramural setting. We have a track record of recruiting substantial numbers of specific cerebrovascular phenotypes (cervical artery dissection, cerebral venous thrombosis, cerebral amyloid angiopathy, etc.). Our consortium of academic rehab hospitals is outstanding. We currently have four trial proposals submitted to StrokeNet in varying stages of the process. Our existing Participant Recruitment and Retention Core (PRRO Core) has played a leadership role in the StrokeNet network. SCANR investigators serve on national StrokeNet steering committees and cores. Our StrokeNet fellows have diverse clinical backgrounds (2 vascular neurologists, 1 PT PhD, 1 OT) and subsequently, they successfully compete for external funding (TL-2, KL-2, AHA). They have opportunities for outstanding research training and mentorship across our Mid- Atlantic institutions, preparing them for productive research careers. SCANR investigators recently successfully established a novel national K12 program for rehabilitation research. We currently have 5 relevant fellowship programs and three adult neurology residencies at the SCANR 2.0 sites. This training joins strong multidisciplinary clinical and research expertise in stroke with much experience in research and career development of clinician scientists.